116 related articles for article (PubMed ID: 37342980)
1. Self-inhibition of HER2 and HER3 at fever temperatures may prevent their hetero-dimerization.
Singh PK; Stan RC
J Biomol Struct Dyn; 2024 Jul; 42(10):5470-5473. PubMed ID: 37342980
[TBL] [Abstract][Full Text] [Related]
2. Structures of the HER2-HER3-NRG1β complex reveal a dynamic dimer interface.
Diwanji D; Trenker R; Thaker TM; Wang F; Agard DA; Verba KA; Jura N
Nature; 2021 Dec; 600(7888):339-343. PubMed ID: 34759323
[TBL] [Abstract][Full Text] [Related]
3. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.
Garner AP; Bialucha CU; Sprague ER; Garrett JT; Sheng Q; Li S; Sineshchekova O; Saxena P; Sutton CR; Chen D; Chen Y; Wang H; Liang J; Das R; Mosher R; Gu J; Huang A; Haubst N; Zehetmeier C; Haberl M; Elis W; Kunz C; Heidt AB; Herlihy K; Murtie J; Schuller A; Arteaga CL; Sellers WR; Ettenberg SA
Cancer Res; 2013 Oct; 73(19):6024-35. PubMed ID: 23928993
[TBL] [Abstract][Full Text] [Related]
4. Enhanced binding at fever temperatures of HER2 in complex with trastuzumab and pertuzumab.
Singh PK; Stan RC
Immunotherapy; 2023 Sep; 15(13):1021-1027. PubMed ID: 37337732
[TBL] [Abstract][Full Text] [Related]
5. Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface.
Collier TS; Diraviyam K; Monsey J; Shen W; Sept D; Bose R
J Biol Chem; 2013 Aug; 288(35):25254-25264. PubMed ID: 23843458
[TBL] [Abstract][Full Text] [Related]
6. Role of HER2/HER3 co-receptor in breast carcinogenesis.
Way TD; Lin JK
Future Oncol; 2005 Dec; 1(6):841-9. PubMed ID: 16556064
[TBL] [Abstract][Full Text] [Related]
7. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
[TBL] [Abstract][Full Text] [Related]
8. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathways: HER3 targeted therapy.
Gala K; Chandarlapaty S
Clin Cancer Res; 2014 Mar; 20(6):1410-6. PubMed ID: 24520092
[TBL] [Abstract][Full Text] [Related]
10. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.
Garrett JT; Sutton CR; Kurupi R; Bialucha CU; Ettenberg SA; Collins SD; Sheng Q; Wallweber J; Defazio-Eli L; Arteaga CL
Cancer Res; 2013 Oct; 73(19):6013-23. PubMed ID: 23918797
[TBL] [Abstract][Full Text] [Related]
11. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
Sakai K; Yokote H; Murakami-Murofushi K; Tamura T; Saijo N; Nishio K
Cancer Sci; 2007 Sep; 98(9):1498-503. PubMed ID: 17627612
[TBL] [Abstract][Full Text] [Related]
12. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
Choi BK; Fan X; Deng H; Zhang N; An Z
Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
[TBL] [Abstract][Full Text] [Related]
13. Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.
Berghoff AS; Bartsch R; Preusser M; Ricken G; Steger GG; Bago-Horvath Z; Rudas M; Streubel B; Dubsky P; Gnant M; Fitzal F; Zielinski CC; Birner P
Breast; 2014 Oct; 23(5):637-43. PubMed ID: 25017122
[TBL] [Abstract][Full Text] [Related]
14. Regulation of cyclooxygenase-2 pathway by HER2 receptor.
Vadlamudi R; Mandal M; Adam L; Steinbach G; Mendelsohn J; Kumar R
Oncogene; 1999 Jan; 18(2):305-14. PubMed ID: 9927187
[TBL] [Abstract][Full Text] [Related]
15. Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?
Menendez JA; Lupu R
Breast Cancer Res; 2007; 9(5):111. PubMed ID: 17983482
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potential HER2 inhibitors from
Balogun TA; Iqbal MN; Saibu OA; Akintubosun MO; Lateef OM; Nneka UC; Abdullateef OT; Omoboyowa DA
J Biomol Struct Dyn; 2022; 40(23):12772-12784. PubMed ID: 34514973
[TBL] [Abstract][Full Text] [Related]
17. A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.
Dey N; Williams C; Leyland-Jones B; De P
Am J Transl Res; 2015; 7(4):733-50. PubMed ID: 26064441
[TBL] [Abstract][Full Text] [Related]
18. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.
Sergina NV; Rausch M; Wang D; Blair J; Hann B; Shokat KM; Moasser MM
Nature; 2007 Jan; 445(7126):437-41. PubMed ID: 17206155
[TBL] [Abstract][Full Text] [Related]
19. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.
Monsey J; Shen W; Schlesinger P; Bose R
J Biol Chem; 2010 Mar; 285(10):7035-44. PubMed ID: 20022944
[TBL] [Abstract][Full Text] [Related]
20. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.
Kang JC; Poovassery JS; Bansal P; You S; Manjarres IM; Ober RJ; Ward ES
MAbs; 2014; 6(2):340-53. PubMed ID: 24492289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
